41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo
Open Access
- 20 December 2019
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 8 (1), e000845
- https://doi.org/10.1136/jitc-2020-000845
Abstract
Background Acute myeloid leukemia (AML) is a hematopoietic malignancy which is biologically, phenotypically and genetically very heterogeneous. Outcome of patients with AML remains dismal, highlighting the need for improved, less toxic therapies. Chimeric antigen receptor T-cell (CART) immunotherapies for patients with refractory or relapse (R/R) AML are challenging because of the absence of a universal pan-AML target antigen and the shared expression of target antigens with normal hematopoietic stem/progenitor cells (HSPCs), which may lead to life-threating on-target/off-tumor cytotoxicity. CD33-redirected and CD123-redirected CARTs for AML are in advanced preclinical and clinical development, and they exhibit robust antileukemic activity. However, preclinical and clinical controversy exists on whether such CARTs are myeloablative. Methods We set out to comparatively characterize in vitro and in vivo the efficacy and safety of 41BB-based and CD28-based CARCD123. We analyzed 97 diagnostic and relapse AML primary samples to investigate whether CD123 is a suitable immunotherapeutic target, and we used several xenograft models and in vitro assays to assess the myeloablative potential of our second-generation CD123 CARTs. Results Here, we show that CD123 represents a bona fide target for AML and show that both 41BB-based and CD28-based CD123 CARTs are very efficient in eliminating both AML cell lines and primary cells in vitro and in vivo. However, both 41BB-based and CD28-based CD123 CARTs ablate normal human hematopoiesis and prevent the establishment of de novo hematopoietic reconstitution by targeting both immature and myeloid HSPCs. Conclusions This study calls for caution when clinically implementing CD123 CARTs, encouraging its preferential use as a bridge to allo-HSCT in patients with R/R AML.Funding Information
- Fundación Josep Carreras Contra la Leucemia
- “la Caixa” Foundation (LCF/PR/HR19/521160011)
- H2020 European Research Council (PoC-2018-811220, CoG-2014-646903)
- Fundación Científica Asociación Española Contra el Cáncer (AECC-Semilla19)
- Fundación Uno entre Cienmil
- Ministerio de Economía y Competitividad (SAF2016-80481-R)
This publication has 56 references indexed in Scilit:
- T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemiaBlood, 2013
- Lineage Switching in Acute Leukemias: A Consequence of Stem Cell Plasticity?Bone Marrow Research, 2012
- Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemiasBlood, 2011
- Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19Blood, 2010
- Bone marrow mesenchymal stem cells from infants with MLL-AF4+ acute leukemia harbor and express the MLL-AF4 fusion geneThe Journal of Experimental Medicine, 2009
- Interleukin (IL)-3/granulocyte macrophage-colony stimulating factor/IL-5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukaemias with mutated FMS-related tyrosine kinase 3 receptorBritish Journal of Haematology, 2009
- Interleukin-3 receptor in acute leukemiaLeukemia, 2003
- Purine Nucleoside Analogues in the Treatment of Myleoid LeukemiasLeukemia & Lymphoma, 2003
- Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cellsBlood, 2001
- Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cellNature Medicine, 1997